Long-term treatment with guselkumab is associated with sustained improvements in joint/skin symptoms and disease activity among patients with active PsA.

A combination of patient-reported outcome measures (PROMs) — including those evaluating general health, pain, quality of life, and disability scores — may serve as an effective tool for detecting ...

A scientific statement has been issued by the American Heart Association regarding the management and diagnosis of Kawasaki disease.

The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

Long-term exposure to wildfire and nonwildfire fine particulate matter (PM2.5) is associated with increased odds of dementia diagnosis.

Individuals born preterm have an increased risk for death from birth through their third and fourth decades of life.

COVID-19, influenza, and RSV vaccination coverage is low among nursing home residents early in the 2024 to 2025 season.

Vaccination of 27- to 45-year-olds against HPV is less cost-effective than vaccination of younger persons (aged 9 to 26 years).

The presence of CVD may increase the risk of developing dementia among older patients with RA, though CVD was not found to mediate this relationship.

Guselkumab demonstrated efficacy for achieving multidomain LDA/remission among patients with PsA and a prior inadequate response to TNF inhibitors.

TAP block provided no clinically meaningful difference vs placebo in pain relief following minimally invasive abdominal surgery.

BRC-002 is an oral botanically-derived cannabinoid agent expected to reduce the pain and comorbidities associated with CRPS. The FDA has granted Orphan Drug designation to BRC-002 (cannabidiol ...